Abbott

Q3 2020
FINANCIAL RESULTS

DIVERSIFIED BUSINESS MODEL DELIVERS STRONG RESULTS

SALES WORLDWIDE

$8.9B in sales

+10.6%[1] on organic basis*

SALES PERFORMANCE ACROSS ABBOTT

$3.2B MEDICAL DEVICES

$2.6B DIAGNOSTICS

$1.1B ESTABLISHED PHARMACEUTICALS

$1.9B NUTRITION

RAISED FULL-YEAR 2020 EPS GUIDANCE[2]

at least **$3.55**

ADJUSTED DILUTED EARNINGS PER SHARE

TAKING COVID-19 TESTING TO A NEW LEVEL

New IgM antibody blood test** on the ARCHITECT® and Alinity® platforms provides a more complete picture of where people are in their recovery

Rapid, reliable and affordable BinaxNOW™ COVID-19 antigen test** and NAVICA™ app deliver results in 15 minutes with no instrumentation required

>100MM COVID-19 tests delivered across testing platforms in 2020

$881MM COVID-19 testing-related sales during the quarter

LEADERSHIP ACROSS OUR STRONG PRODUCT PORTFOLIO

Diagnostics SALES UP 39%[3] ON AN ORGANIC BASIS*

- Growth led by Molecular Diagnostics (up 314%) and Rapid Diagnostics (up 83%)[3]
- Focused on creating and manufacturing a diverse portfolio of COVID-19 testing technologies at mass scale**


BinaxNOW


ID NOW™


ARCHITECT i1000SR and i2000SR


Alinity i


m2000® RealTime System


Alinity m



- Announced CE Mark for FreeStyle Libre® 3, the latest generation of our leading continuous glucose technology
- Announced CE Mark for Libre Sense, allowing athletes to better monitor and understand how glucose management can improve performance

FreeStyle Libre SALES UP 36%[4] ON AN ORGANIC BASIS*

Advances in Heart Devices

- Announced CE Mark for next-generation MitraClip™ G4 heart device
- Abbott's fourth-generation MitraClip treats mitral regurgitation, or a leaky heart valve, without open-heart surgery

*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated October 21, 2020, available at www.abbottinvestor.com.

**These tests have not been FDA cleared or approved. These tests have been authorized by FDA under EUAs for use by authorized laboratories and have been authorized only for the detection of nucleic acid from SARS-CoV-2 or detection of IgG antibodies against SARS-CoV-2, and not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

1. On a GAAP basis, third-quarter Abbott sales increased 9.6%. 2. Adjusted diluted EPS excludes specified items. Abbott forecasts specified items for the full-year 2020 of $1.20 primarily related to intangible amortization, acquisition-related expenses, restructuring and cost reduction initiatives and other net expenses. On a GAAP basis, full-year EPS guidance is at least $2.35. 3. On a GAAP basis, Worldwide Diagnostics sales increased 38%; Molecular Diagnostics sales increased 313%; and Rapid Diagnostics sales increased 83%. 4. On a GAAP basis, FreeStyle Libre sales increased 38%.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on Abbott's operations and financial results, that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2019 and in Item 1A, "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.